Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BAY3375968

Phase 1Small molecule

BAY3375968 is one of 45 small molecule programs targeting Solid Tumor. It is currently in Phase 1.

2

Indications

1

Total Trials

1

Active Trials

44

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Advanced Solid TumorsActive, not recruiting

Solid TumorPhase 1

Active, not recruiting

Advanced Solid TumorsPhase 1

Active, not recruiting

Competition

Competitive Landscape

171 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Keytruda

Lenvima

Lynparza

Bavencio

Investigator's Choice of Chemotherapy

CCSPC Megalith Biopharmaceutical Co.,Ltd.

MK-4280

MK-4280A

INCB161734

Lumakras

Abraxane

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Solid Tumor

NCT05537740

Clinical

Trials by Indication[1]

Solid Tumor1 trial

First-in-human Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Anti-CCR8 Antibody BAY 3375968 as Monotherapy and in Combination With Pembrolizumab in Participants With Selected Advanced Solid Tumors

Active, not recruiting· Bayer logo

Bayer·Phase 1·NCT05537740·129 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BAY3375968. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BAY3375968 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BAY3375968. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Bayer

Related News